Oculis S.A., a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments for back- and front-of-the-eye diseases, today announced the appointments of Eric Donnenfeld, M.D., and Pr. Ramin Tadayoni, M.D., Ph.D., to its Scientific Advisory Board (SAB).
“I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that can treat both back- and front-of-the eye diseases,” said Riad Sherif, M.D., Chief Executive Officer of Oculis. “Back-of-the-eye diseases, such as diabetic macular edema, currently require invasive treatments such as intraocular injections or intravitreal drug-releasing implants. The invasiveness of the current options creates a real treatment burden for patients and does not allow for early intervention. OCS-01, our lead product candidate based on our proprietary solubilizing nanoparticle technology, could potentially become the first ever topical treatment for DME.”
Dr. Donnenfeld is a trustee of Dartmouth Medical School and a clinical professor of ophthalmology at New York University. He is past president of American Society of Cataract and Refractive Surgery, president-elect of the International Intraocular Implant Society and is the editor-in-chief of EyeWorld. He has written over 200 peer review papers and 60 book chapters and books. He is a Fellow of the American Academy of Ophthalmology and has received its Lifetime Achievement Award.
Dr. Tadayoni is Professor of Ophthalmology at University of Paris and Head of the department of Ophthalmology at Lariboisière University Hospital (Paris, France). He has authored more than 140 medical and scientific articles and has made numerous contributions to ophthalmology textbooks. Dr. Tadayoni completed undergraduate training in medicine at the University of Marseille, and his M.D. and internship at Paris V University. He completed his studies with a retina fellowship at Lariboisière University Hospital. Simultaneously, he pursued his Ph.D. in Science at Paris VII University and the Paris Vision Institute.
“Dr. Donnenfeld and Professor Tadayoni are highly respected and distinguished ophthalmic physicians, and I am delighted that they are joining the Oculis Scientific Advisory Board,” said Dr. Pravin Dugel, Chairman of the Scientific Advisory Board. “Their exemplary work in the field of ophthalmology and their highly complementary expertise in back- and front-of-the-eye diseases will prove to be very valuable.”